CytomX Therapeutics, Inc. (CTMX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.36
- As of
Kresmion compiles this page from CTMX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CytomX Therapeutics, Inc. (CTMX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
See the full CTMX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CTMX on one page. Preview it with sample data, then open it live with a free account.
Preview the CTMX dossierActive events for CTMX
- high13F: large increase
CITADEL ADVISORS LLC added +73% to CTMX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +156% to CTMX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +5975% to CTMX (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 54% of CTMX (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +52% to CTMX (2026Q2)
FREE, NO ACCOUNT
Every event on CTMX, as it fires
You are seeing 5 of 14 events recorded on CTMX since 2026-05-16.
The five above all landed on 2026-08-16. The other 9 were recorded on 3 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CTMX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 23284F105 · 2026Q2 | $29.3M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 23284F105 · 2026Q2 | $15.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 23284F105 · 2026Q2 | $11.7M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 23284F105 · 2026Q2 | $6.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CTMX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CTMX against its peers
CTMX's operating margin of -29.3% ranks in the 73rd percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | CTMX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 76.2M USD | 9.7M USD | 59 | 15 |
| Gross margin | n/a | 69.9% | n/a | 5 |
| Operating margin | -29.3% | -70.8% | 73 | 12 |
| Net margin | -22.8% | -89.9% | 73 | 12 |
| Return on equity | -17.5% | -54.4% | 79 | 20 |
Peers (21): FTH, OCS, VALN, CBIO, MNPR, NGNE, ARVN, ENTX, DMAC, EPRX, MPLT, RGNX, STTK, MYGN, OLMA, PBYI, OVID, MDXG, PRTA, IRWD, ALLO. Left out: BLSM (no annual filing), DRUG (period gap), AGMB (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CTMX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CTMX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CTMX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.